CureDuchenne has submitted comments to the U.S. Food and Drug Administration (FDA) on several proposed policies that could affect how new gene therapies and other genetic treatments are developed and reviewed for Duchenne muscular dystrophy, Becker muscular dystrophy, and other rare diseases.
As a nonprofit organization focused on improving lives of people with Duchenne, CureDuchenne works with patients, families, researchers, doctors, companies, and regulators to help bring promising therapies to people who need them as quickly and safely as possible.
Why These FDA Policies Matter for Families
Over the last decade, treatment options for Duchenne have grown significantly. Several therapies have been approved, and many more are being studied, including gene therapies, exon-skipping treatments, and gene-editing technologies.
While this progress brings hope, Duchenne remains a serious, progressive disease. Muscle loss caused by Duchenne cannot be reversed, and many individuals still have few or no treatment options. For families living with Duchenne, time is critical.
The FDA Policies Reviewed
CureDuchenne provided feedback on four FDA proposals that could influence future treatment development:
National Priority Voucher Program – A proposed program that could speed up the review of treatments that address major public health needs.
Genome Editing Safety Guidance – Recommendations for evaluating the safety of gene-editing therapies.
Individualized Therapy Framework – Guidance for developing personalized treatments designed for specific genetic mutations.
Using Existing Scientific Knowledge – Guidance on how previous research and experience can help streamline the development of new gene-editing therapies.
CureDuchenne supports the FDA’s role in ensuring treatments are safe and effective. At the same time, the organization believes that promising therapies should move through the development process as efficiently as possible so patients are not waiting unnecessarily.
Families living with Duchenne and Becker muscular dystrophy cannot wait. Regulatory policies should protect patients while recognizing the urgency of progressive diseases.
What CureDuchenne Recommended
Across all four FDA initiatives, CureDuchenne emphasized several key priorities:
Clear Guidance for Researchers
Scientists and companies need a clear understanding of what evidence the FDA requires when reviewing new treatments. Because Duchenne is a rare disease, large clinical trials can be difficult. CureDuchenne encouraged the FDA to continue considering other scientific tools, such as biomarkers and natural history data, when appropriate.
Balanced Safety Reviews
New technologies like genome editing must be carefully evaluated for safety. However, CureDuchenne also noted that delays in treatment can have real consequences for people living with progressive diseases like Duchenne.
Looking at the Full Picture
No single measurement tells the entire story.
CureDuchenne encouraged FDA to continue considering all available evidence, including disease biology, laboratory research, biomarkers, and clinical data, when evaluating new therapies.
Keeping Patients and Families at the Center
Patients and families understand the impact of Duchenne better than anyone.
Their experiences, treatment goals, and perspectives on benefit-risk should continue to play an important role in FDA decision-making.
Looking Ahead
Scientific progress in Duchenne has never been greater, but significant challenges remain.
CureDuchenne will continue to work with the FDA, researchers, clinicians, industry partners, and the broader rare disease community to support policies that are science-based, transparent, and focused on patients.
By helping create a regulatory environment that encourages innovation while maintaining high safety standards, CureDuchenne hopes to accelerate access to new treatments for everyone living with Duchenne.
The post CureDuchenne Submits Comments to FDA on Future Gene Therapies for Duchenne Muscular Dystrophy and Other Rare Diseases appeared first on CureDuchenne.